Orange Is the New Black: FTC Targets Improper Patent Listings As Anticompetitive

View this email online. Orange Is the New Black: FTC Targets Improper Patent Listings As Anticompetitive September 18, 2023 By Joseph M. Miller, Sherwet H. Witherington Nearly a year after announcing the expansion of its Section 5 “standalone authority," which encompasses conduct outside the scope of the foundational federal antitrust laws, the FTC voted unanimously to issue a policy statement explaining how its authority applies to the listing of brand-name drug patents in the Food and Drug Administration’s (FDA) Orange Book. Read more… // Questions? Contact a Mintz Professional. // More Mintz Insights here MINTZ on LinkedIn MINTZ on facebook MINTZ on Twitter BOSTON LOS ANGELES NEW YORK SAN DIEGO SAN FRANCISCO TORONTO WASHINGTON DC Copyright © 2023 Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. Please review our Privacy Statement. If you would like to contact us with questions about our privacy or data protection practices, please contact our Privacy Officer via email at [email protected]. This email was sent to mintz Smith at [email protected] You can  or . Share this email safely here.